Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471

Fu, Xiaoxiao; Wang, Jing; Cai, Huaying; Jiang, Hong; Han, Shu

doi:10.3390/ph18070985

Open AccessCorrection

Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471

by

Xiaoxiao Fu

^1,†,

Jing Wang

^2,†,

Huaying Cai

²,

Hong Jiang

² and

Shu Han

^1,*

¹

Institute of Anatomy, Medical College, Zhejiang University, Hangzhou 310058, China

²

Department of Neurology, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou 310058, China

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Pharmaceuticals 2025, 18(7), 985; https://doi.org/10.3390/ph18070985

Submission received: 26 May 2025 / Accepted: 30 May 2025 / Published: 30 June 2025

(This article belongs to the Section Biopharmaceuticals)

Download

Browse Figure

Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 7 as published. In Figure 7, the magnification of subfigure D,H,L is different from other subfigures. The corrected Figure 7 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

Fu, X.; Wang, J.; Cai, H.; Jiang, H.; Han, S. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471. [Google Scholar] [CrossRef] [PubMed]

Figure 7. Electron micrographs show the ultrastructural morphology of the (A–D) sham control, (E–H) vehicle, and (I–L) C + A groups. The sham control rats showed (A) neuronal nuclei with uncondensed chromatin (red arrow in (A)). There was (B) no tissue edema or blood vessel leakage (red arrow in (B)). Intact tight junctions (red arrow in (C)) and myelinated axons surrounded by dark, ring-shaped myelin sheaths were also observed (red arrows in (C,D)). In the vehicle group, (E) neuronal apoptosis was evidenced by shrunken nuclei with marginated, fragmented, and condensed nuclear chromatin (showed by two arrows in (E)). (F) Severe blood vessel leakage and tissue edema in the extracellular space surrounding the vessels (yellow arrow in (F)). (G) Loosening of tight junctions between the endothelium (purple arrow in (G)). (H) Myelin sheath loosening and splitting (green arrow in (H)). Treatment with C16 plus Ang-1 reduced morphological changes of the nuclei (orange arrow in (I)), alleviated perivascular edema (orange arrow in (J)), prevented destruction of tight junctions (orange arrow in (K)), and decreased myelin sheath splitting (orange arrow in (L)).

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Fu, X.; Wang, J.; Cai, H.; Jiang, H.; Han, S. Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471. Pharmaceuticals 2025, 18, 985. https://doi.org/10.3390/ph18070985

AMA Style

Fu X, Wang J, Cai H, Jiang H, Han S. Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471. Pharmaceuticals. 2025; 18(7):985. https://doi.org/10.3390/ph18070985

Chicago/Turabian Style

Fu, Xiaoxiao, Jing Wang, Huaying Cai, Hong Jiang, and Shu Han. 2025. "Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471" Pharmaceuticals 18, no. 7: 985. https://doi.org/10.3390/ph18070985

APA Style

Fu, X., Wang, J., Cai, H., Jiang, H., & Han, S. (2025). Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471. Pharmaceuticals, 18(7), 985. https://doi.org/10.3390/ph18070985

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Fu et al. C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction. Pharmaceuticals 2022, 15, 471

Error in Figure

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI